The ZNF217 biomarker predicts low-and high-risk oncotype DX® recurrence score in ER-positive invasive breast cancers

Pascale A. Cohen, Olivier Loudig, Christina Liu, Joseph Albanese, Susan Fineberg

Research output: Contribution to journalArticlepeer-review

2 Scopus citations
Original languageEnglish (US)
Article number524
JournalFrontiers in Pharmacology
Issue numberMAY
StatePublished - 2019


  • Biomarker
  • Breast cancer
  • Estrogen-receptor positive
  • Expression
  • Oncotype DX®
  • ZNF217

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this